生物标志物与剂量学参数在个性化90Y玻璃微球选择性内放射治疗患者总生存与无进展生存预测中的作用:一项初步机器学习研究
这项初步回顾性分析纳入17例接受90Y选择性内放射治疗(SIRT)的肝细胞癌(HCC)患者,采用个体化治疗计划与体素剂量学,从99mTc-MAA和90Y SPECT/CT图像提取289项剂量体积约束(DVC)及16项临床生物标志物,用Cox比例风险模型与机器学习模型预测总生存(OS)和无进展生存(PFS)。中位OS为11个月(95%CI:8.5,13.09),中位PFS为7个月(95%CI:5.6,10.98);腹水、SIRT目的、AST水平和MAA-Dose-V205(%)-TL与OS相关,90Y衍生参数与PFS相关而与OS无关。
要点
- 17例HCC患者接受90Y玻璃微球SIRT,中位OS 11个月(95%CI:8.5,13.09),中位PFS 7个月(95%CI:5.6,10.98)。
- 单因素分析中腹水(HR 9.2[1.8,47])、SIRT目的(HR 0.066[0.0057,0.78])、AST水平(HR 0.1[0.012-0.86])和MAA-Dose-V205(%)-TL(HR 8.5[1,72])为OS预测因子。
- 90Y衍生参数与PFS相关而非OS;多因素机器学习模型预测OS的最高C-index为0.94±0.13,VH.VIMP联合广义线性模型网络预测OS的C-index为0.93±0.14,KM分层log-rank P=0.023。
核心结论
- 这项初步研究证实基线临床生物标志物和剂量学参数在预测治疗结局中的作用,为建立剂量-效应关系铺路。
- 研究还证明机器学习结合这些特征可作为90Y-SIRT治疗前后临床管理的有用工具。
研究设计与样本
- 初步回顾性分析,纳入17例接受90Y SIRT治疗的肝细胞癌患者,采用个体化治疗计划与体素剂量学。
- 勾画肿瘤肝(TL)、正常灌注肝(NPL)和全正常肝(WNL)三个结构,从99mTc-MAA和90Y SPECT/CT图像计算的物理剂量与生物有效剂量(BED)图的剂量体积直方图中提取289项剂量体积约束(DVC)。
- 以DVC和16项临床生物标志物为特征进行单因素和多因素分析,单因素用Cox比例风险比(HR),并计算每个特征的HR与一致性指数(C-Index)。
- 多因素分析采用8种策略对多种模型与特征选择(FS)方法进行交叉组合,以三折嵌套交叉验证框架的平均C-Index评估各模型性能,并用Kaplan-Meier(KM)曲线评估单因素与机器学习模型性能。
主要发现
- 中位OS为11个月(95%CI:8.5,13.09),中位PFS为7个月(95%CI:5.6,10.98)。
- 单因素分析显示腹水(HR 9.2[1.8,47])、SIRT目的(段切除、叶切除、姑息)(HR 0.066[0.0057,0.78])、天冬氨酸氨基转移酶(AST)水平(HR 0.1[0.012-0.86])和MAA-Dose-V205(%)-TL(HR 8.5[1,72])为OS的预测因子。
- 90Y衍生参数与PFS相关而与OS无关。
- 剂量学参数中,MAA-Dose-V205(%)-WNL、MAA-BED-V400(%)-WNL(HR 13[1.5-120])以及90Y-Dose-mean-TL、90Y-D50-TL-Gy、90Y-Dose-V205(%)-TL、90Y-Dose-D50-TL-Gy、90Y-BED-V400(%)-TL(HR 15[1.8-120])与PFS高度相关。
- 多因素分析中机器学习预测OS的最高C-index为0.94±0.13,来自Variable Hunting-variable-importance(VH.VIMP)特征选择联合Cox比例风险模型并使用临床特征。
关键数值与推荐
- OS单因素预测因子:腹水HR 9.2[1.8,47]、SIRT目的HR 0.066[0.0057,0.78]、AST水平HR 0.1[0.012-0.86]、MAA-Dose-V205(%)-TL HR 8.5[1,72]。
- PFS相关剂量学参数:MAA-Dose-V205(%)-WNL、MAA-BED-V400(%)-WNL HR 13[1.5-120]、90Y-Dose-mean-TL、90Y-D50-TL-Gy、90Y-Dose-V205(%)-TL、90Y-Dose-D50-TL-Gy、90Y-BED-V400(%)-TL HR 15[1.8-120]。
- 预测OS的机器学习模型最高C-index为0.94±0.13(VH.VIMP特征选择联合Cox比例风险模型,临床特征)。
- VH.VIMP联合广义线性模型网络预测OS(治疗策略特征)C-Index 0.93±0.14,KM曲线分层log-rank P=0.023。
临床怎么用
- 作者认为,基线临床生物标志物和剂量学参数可用于预测90Y-SIRT的治疗结局,为建立剂量-效应关系铺路。
- 作者认为,机器学习结合这些特征可作为90Y-SIRT治疗前后临床管理的有用工具。
局限性
- 原文称本研究为初步(preliminary)研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Overall Survival (OS) and Progression-Free Survival (PFS) analyses are crucial metrics for evaluating the efficacy and impact of treatment. This study evaluated the role of clinical biomarkers and dosimetry parameters on survival outcomes of patients undergoing 90Y selective internal radiation therapy (SIRT). MATERIALS/METHODS: This preliminary and retrospective analysis included 17 patients with hepatocellular carcinoma (HCC) treated with 90Y SIRT. The patients underwent personalized treatment planning and voxel-wise dosimetry. After the procedure, the OS and PFS were evaluated. Three structures were delineated including tumoral liver (TL), normal perfused liver (NPL), and whole normal liver (WNL). 289 dose-volume constraints (DVCs) were extracted from dose-volume histograms of physical and biological effective dose (BED) maps calculated on 99mTc-MAA and 90Y SPECT/CT images. Subsequently, the DVCs and 16 clinical biomarkers were used as features for univariate and multivariate analysis. Cox proportional hazard ratio (HR) was employed for univariate analysis. HR and the concordance index (C-Index) were calculated for each feature. Using eight different strategies, a cross-combination of various models and feature selection (FS) methods was applied for multivariate analysis. The performance of each model was assessed using an averaged C-Index on a three-fold nested cross-validation framework. The Kaplan-Meier (KM) curve was employed for univariate and machine learning (ML) model performance assessment. RESULTS: The median OS was 11 months [95% CI: 8.5, 13.09], whereas the PFS was seven months [95% CI: 5.6, 10.98]. Univariate analysis demonstrated the presence of Ascites (HR: 9.2[1.8,47]) and the aim of SIRT (segmentectomy, lobectomy, palliative) (HR: 0.066 [0.0057, 0.78]), Aspartate aminotransferase (AST) level (HR:0.1 [0.012-0.86]), and MAA-Dose-V205(%)-TL (HR:8.5[1,72]) as predictors for OS. 90Y-derived parameters were associated with PFS but not with OS. MAA-Dose-V205(%)-WNL, MAA-BED-V400(%)-WNL with (HR:13 [1.5-120]) and 90Y-Dose-mean-TL, 90Y-D50-TL-Gy, 90Y-Dose-V205(%)-TL, 90Y-Dose- D50-TL-Gy, and 90Y-BED-V400(%)-TL (HR:15 [1.8-120]) were highly associated with PFS among dosimetry parameters. The highest C-index observed in multivariate analysis using ML was 0.94 ± 0.13 obtained from Variable Hunting-variable-importance (VH.VIMP) FS and Cox Proportional Hazard model predicting OS, using clinical features. However, the combination of VH. VIMP FS method with a Generalized Linear Model Network model predicting OS using Therapy strategy features outperformed the other models in terms of both C-index and stratification of KM curves (C-Index: 0.93 ± 0.14 and log-rank p-value of 0.023 for KM curve stratification). CONCLUSION: This preliminary study confirmed the role played by baseline clinical biomarkers and dosimetry parameters in predicting the treatment outcome, paving the way for the establishment of a dose-effect relationship. In addition, the feasibility of using ML along with these features was demonstrated as a helpful tool in the clinical management of patients, both prior to and following 90Y-SIRT.
引用
- Mansouri Z, Salimi Y, Hajianfar G, et al. The role of biomarkers and dosimetry parameters in overall and progression free survival prediction for patients treated with personalized 90Y glass microspheres SIRT: a preliminary machine learning study. Eur J Nucl Med Mol Imaging. 2024. PMID: 38981950. doi:10.1007/s00259-024-06805-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。